Credit: Getty Images The latest data released at ASH 2025 highlight how targeted therapies are changing the way CLL is managed. Significant treatment options with targeted therapies are changing the ...

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...

Pirtobrutinib showed an 80% reduction in PFS compared with BendaR in treatment-naïve CLL/SLL patients, indicating its potential as a first-line therapy. The trial demonstrated pirtobrutinib's superior ...

Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...

Jaypirca improved progression-free survival in CLL/SLL patients compared to bendamustine plus rituximab, reducing disease progression or death risk by 80%. This non-covalent BTK inhibitor offers a ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...

Jaypirca demonstrated non-inferiority to Imbruvica in treating CLL and SLL, with an 87% overall response rate compared to 78.6% for Imbruvica. As a non-covalent BTK inhibitor, Jaypirca offers ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...